Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents

Incretin-based therapies: can we achieve glycemic control and cardioprotection?

(2013) Franca S Angeli et al.   JOURNAL OF ENDOCRINOLOGY

Drug Treatment of Obesity in Cardiovascular Disease

(2012) Marietta Charakida et al.   American Journal of Cardiovascular Drugs

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Anti-Obesity Drugs: A Review about Their Effects and Safety

(2012) Jun Goo Kang et al.   Diabetes & Metabolism Journal

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

(2011) David B. Allison et al.   Obesity

Cardiovascular Risk-Benefit Profile of Sibutramine

(2010) A.J. Scheen   American Journal of Cardiovascular Drugs

How ephedrine escaped regulation in the United States: A historical review of misuse and associated policy

(2010) Joseph Palamar   HEALTH POLICY

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serotonergic drugs and valvular heart disease

(2009) Richard B Rothman et al.   Expert Opinion On Drug Safety

Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment

(2009) X.-P. Huang et al.   MOLECULAR PHARMACOLOGY

Pulmonary hypertension: therapeutic targets within the serotonin system

(2008) Y Dempsie et al.   BRITISH JOURNAL OF PHARMACOLOGY

Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy

(2008) Fabrice Jaffré et al.   CIRCULATION RESEARCH